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Abstract
Background: Patient satisfaction with antipsychotic treatment is important. Limited evidence suggests that
satisfaction is associated with symptom improvement and compliance. Predictors of patient satisfaction with
antipsychotic medication were examined in a study of patients with a recent exacerbation of schizophrenia.
Methods: Data are from a randomized, double-blind trial comparing risperidone (n = 152), quetiapine (n = 156),
and placebo (n = 73). Medication Satisfaction Questionnaire (MSQ) was completed after 14 days of treatment and
after 6 weeks at last study visit.
Results: Medication satisfaction at both time points was significantly associated in multiple regression analysis
with improvement on 3 Positive and Negative Syndrome Scale (PANSS) factor scores (positive symptoms p < .01;
uncontrolled hostility/excitement, p < .0005; anxiety/depression, p < .04) and treatment with risperidone (p <
.03); at day 14, significant association was also found with older age (p = .01). At both time points, predictor
variables explained over 30% of the variance in medication satisfaction. Change in Hamilton Depression Scale,
prolactin levels, sex, and reported adverse events of extrapyramidal symptoms, sedation, and movement
disorders were not significant predictors of satisfaction. Lower level of medication satisfaction at day 14 was
associated with earlier discontinuation in the trial at week 6 end point. A focused principal components analysis
of PANSS factors and MSQ suggested that medication satisfaction relates to 3 groups of factors in descending
order of magnitude: lower levels of (a) uncontrolled hostility/excitement, (b) positive symptoms, and (c) negative
symptoms, disorganized thoughts, and anxiety/depression.
Conclusion: Results give further support that treatment satisfaction is positively associated with symptom
improvement, particularly psychotic symptoms, and suggest that satisfaction may also be related to compliance,
as those who were more satisfied remained in the trial for a longer period of time.
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Background
Patient satisfaction with antipsychotic treatment is an
important outcome. There is limited evidence suggesting
that it is positively associated with compliance [1],
improved clinical outcomes [2-6], and quality of life [7].
Yet there is a lack of prospective studies examining the
association of patient satisfaction, medication compli-
ance, and treatment outcomes [8].
While considerable attention has been given to the effi-
cacy and safety of second-generation antipsychotics, little
attention in clinical trials has been given to medication
compliance, subjective tolerability, and satisfaction with
treatment [9,10]. There are some data from naturalistic
studies suggesting greater satisfaction among patients
treated with second-generation than first-generation
antipsychotic medications [11,12]. It is surprising that
patient satisfaction, which may be a key advantage of sec-
ond-generation antipsychotics, has not received adequate
research attention. This has led to the recognition that
there is a need for well-designed studies of treatment sat-
isfaction of second-generation antipsychotic medications
before firm conclusions can be reached [13]. In the cur-
rent study, we examined predictors and consequences of
patient satisfaction with atypical antipsychotic medica-
tion in a study of patients with a recent exacerbation of
schizophrenia treated with risperidone, quetiapine, or
placebo.
Methods
Study design
Data are from a 2-phase, double-blind, international, 6-
week study conducted at 30 sites. The safety and efficacy
results and methodology are reported elsewhere [14].
Inpatients with schizophrenia or schizoaffective disorder
with a recent exacerbation of psychotic symptoms were
randomly assigned to receive risperidone, quetiapine, or
placebo in a 2:2:1 ratio. Patients were treated with risperi-
done, quetiapine, or placebo monotherapy for the first 2
weeks; during the subsequent 4 weeks, investigators were
permitted to prescribe additional psychiatric medications
as necessary. Study medications were increased from days
1 to 5 according to a fixed schedule. Target doses at day 5
were 4 or 6 mg/day of risperidone and 400 or 600 mg/day
of quetiapine. On day 8, the dose of quetiapine could be
increased, in a blinded fashion, to 600 or 800 mg/day.
Patients were maintained on their day-8 dose for the
remainder of the study. Mean doses at day 14 were 4.7 ±
0.9 mg/day of risperidone and 579.5 ± 128.9 mg/day of
quetiapine. Dosing regimens for risperidone and quetiap-
ine were in accordance with the prescribing information
for each drug and also reflected clinical and research prac-
tices for treating patients with acute exacerbations of
schizophrenia [15,16].
The trial was conducted in accordance with current Inter-
national Conference on Harmonization-Good Clinical
Practice guidelines and the Declaration of Helsinki and its
subsequent revisions. All patients deemed competent by
the investigator provided written informed consent prior
to study participation. If a patient was deemed not legally
competent, then consent was obtained from the patient
and an authorized representative. Ethical approval was
obtained by Institutional Review Boards at each investiga-
tors site.
Exclusion criteria included a co-morbid Axis I diagnosis
(with the exception of substance abuse/dependence), bor-
derline personality disorder, mental retardation, or a clin-
ically significant medical illness. Also excluded were
patients who had received risperidone or quetiapine
within 7 days of baseline, clozapine within 60 days, or
depot antipsychotics or electroconvulsive therapy within
defined time periods.
Baseline characteristics were similar in the 3 treatment
arms [14]. The mean (± SD) age of patients was 34.8 ± 9.7
(median 35; range 18–63) years, and 60% were male. The
mean (± SD) baseline Positive and Negative Syndrome
Scale (PANSS) was 95.8 ± 18.5 and Clinical Global
Impressions (CGI)-Severity was 5.4 ± 0.5. Eighty-seven
percent of the patients completed the day 14 visit and
75% completed day 42.
Efficacy and safety assessment
Assessments were conducted on days 1, 3, 5, 7, 9, 14, 21,
28, and 42. Efficacy measures included the PANSS [17];
the 17-item Hamilton-Depression Scale (HAM-D) [18];
and the CGI-Severity and CGI-Change scales [19]. Safety
measures included the Simpson Angus Scale (SAS) [20]
and the Barnes Akathisia Scale (BAS) [21], which were
administered at baseline, day 14, 28, and 42. Reports of
adverse events were collected at all visits, and laboratory
assessments (including prolactin) were performed at
baseline and days 14 and 42.
Medication satisfaction
Patient satisfaction with the study medication was
assessed using the Medication Satisfaction Questionnaire
(MSQ) a 1-item global patient-rated scale. Specifically,
patients were asked to respond on a 7-point scale, ranging
from extremely dissatisfied (1) to extremely satisfied (7),
to the following: "The way you feel about taking your
study medication is". The MSQ was derived from work
using a much longer and more detailed published scale
[22] and is similar to items included in other scales [3].
There has been much debate in the field regarding the cor-
rect methodological approach for measuring patient satis-
faction and no consensus has yet been reached. It has
been argued that lengthier scales typically contain a largeBMC Psychiatry 2006, 6:45 http://www.biomedcentral.com/1471-244X/6/45
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number of items that are irrelevant and thus are more sus-
ceptible to providing inaccurate results. Longer instru-
ments of patient satisfaction have generally not
demonstrated better validity than 1-item global ratings
[23]. This is of particular relevance for acutely severely ill
psychotic patients who could not reasonably be expected
to complete a lengthy patient-rated instrument.
Data analysis
We attempted to predict medication satisfaction at days
14 and 42 using univariate linear regression followed by
step-wise multiple linear regression. The predictor varia-
bles chosen were change from baseline in symptoms (5
PANSS factor scores [24] and HAM-D scale), treatment
regimen (risperidone, quetiapine, or placebo), reported
adverse events of extrapyramidal symptoms (EPS) or seda-
tion, movement disorders (BAS, SAS), prolactin levels,
age, and sex. We also examined whether greater initial
treatment satisfaction as measured at day 14 was associ-
ated with time in trial to end point. This was done by com-
puting the mean time (in days) in trial for each response
category on the MSQ.
Finally, to understand the relationship between psychotic
symptomatology and medication satisfaction we exam-
ined the association of the MSQ and the 5 PANSS factors
[24]. This was done first by examining the correlations of
the MSQ and PANSS factors. To graphically represent and
examine the relationship between Medication Satisfaction
and the five PANSS factors we used focused principal
components analysis (PCA) [25]. Focused PCA is a special
type of PCA designed to describe and understand relation-
ships between a set of quantitative variables, with a partic-
ular interest in the dependencies of one variable, in this
case MSQ, with the others, in this case the PANSS factors.
The relationships between nondependent variables are
interpreted as in a PCA: correlated variables are close or
diametrically opposite (for negative correlations); inde-
pendent variables make a right angle with the origin.
Focused PCA was conducted using R (version 2.0.1) soft-
ware, module PSY (version 0.6).
Results and Discussion
As shown in Table 1, medication satisfaction at both time
points was significantly associated with improvement
(change from baseline to each time point) on 3 PANSS
factor scores (positive symptoms, uncontrolled hostility/
excitement, anxiety/depression), treatment with risperi-
done, and at day 14 also higher age. At both time points,
these predictor variables explained over 30% of the vari-
ance in medication satisfaction in a multiple regression
analysis. Change in HAM-D scale, prolactin levels, sex,
Table 1: Predictors of patient satisfaction with antipsychotic medication
Day 14 Day 42 (end point)
Univariate regression Step-wise multiple 
regression R2 = .31
Univariate regression Step-wise multiple 
regression R2 = .33
T = p = R2 F  =p  =T  =p  =R 2 F = p =
Symptom change 
PANSS factors Positive
-10.11 <.0001 .26 21.98 <.0001 -9.40 <.0001 .23 6.39 .01
Negative -5.22 <.0001 .11 -5.69 <.0001 .12 3.63 .06
Disorganized thoughts -5.89 <.0001 .13 -5.64 <.0001 .12
Hostility/excitement -9.25 <.0001 .23 14.11 .0002 -8.69 <.0001 .21 12.46 .0005
Anxiety/depression -5.80 <.0001 .13 4.03 .04 -7.43 <.0001 .17 16.85 <.0001
HAM-D -5.33 <.0001 .11 NS -5.06 <.0001 .11 NS
Adverse events 
Prolactin level
.439 .66 .04 -.666 .50 .04 NS
EPS reported -.95 .34 .04 2.89 .09 .60 .55 .04 NS
Sedation reported -1.21 .23 .05 1.91 .06 .05 NS
BAS global (present) -1.42 .16 .05 -.88 .38 .04
SAS total (present) -.50 .62 .04 -.25 .80 .04
Demographics Age 1.84 .07 .05 6.17 .01 .58 .56 .04
Gender (male) .46 .64 .04 .37 .71 .04
Antipsychotic use NA* -2.69 .007 .06 8.03 .004
Risperidone 3.48 .0006 .04 4.80 .03 3.06 .002 4.94 .027
Quetiapine 1.15 .25 .04 .60 .44 .83 .41 .00 .98
* Antipsychotic use appeals after 14 days.
Abbreviations: PANSS, Positive and Negative Syndrome Scale; HAM-D, Hamilton Depression Scale; NS, not significant; EPS, extrapyramidal 
symptoms; BAS, Barnes Akathisia Scale; SAS, Simpson Angus Scale.BMC Psychiatry 2006, 6:45 http://www.biomedcentral.com/1471-244X/6/45
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and reported adverse events of EPS, sedation, and move-
ment disorders (BAS, SAS) were not significant predictors
of satisfaction.
Figure 1 shows the mean time (in days) in trial until week
6 end point by medication satisfaction after 14 days of
treatment. Patients who were satisfied clearly remained in
the study significantly longer than those who were not sat-
isfied.
The correlation of the PANSS factors and MSQ (Table 2)
and the focused PCA (Figure 2) suggest that medication
satisfaction relates to 3 groups of factors in descending
order of magnitude: lower levels of (a) uncontrolled hos-
tility/excitement, (b) positive symptoms, and (c) negative
symptoms, disorganized thoughts, and anxiety/depres-
sion. In the focused PCA (Figure 2) as the rings get closer
to the center they reflect a higher correlation with the
MSQ. The positive symptoms factor and uncontrolled
hostility/excitement were the most closely correlated with
the MSQ, followed by negative symptoms and disorgan-
ized thoughts, with little association with anxiety/depres-
sion.
Conclusion
The results give further support that treatment satisfaction
is positively associated with symptom improvement, par-
ticularly psychotic symptoms. The results also suggest that
treatment satisfaction may also be related to compliance,
since patients who were more satisfied remained in the
trial for a longer time. A single-item measure of patient
satisfaction was sensitive to clinical improvement and
adherence. Patient-reported outcomes, such as satisfac-
tion with medications, offer a way of measuring both effi-
cacy and tolerability features of treatments from a patient
perspective. As rated by the MSQ, data suggest that the sig-
nificantly greater patient satisfaction with risperidone
than quetiapine or placebo may be related to the greater
symptom reduction associated with risperidone. This is
suggested by both regression models in which a reduction
in psychotic symptoms consistently emerged as a signifi-
cant predictor of medication satisfaction. Further, in the
multiple regression model, treatment with risperidone,
but not quetiapine, and increasing age were also predic-
tive of medication satisfaction. Our finding that patient
satisfaction is related to improvement of positive symp-
toms and not negative symptoms might be related to the
duration of the trial. As was the case in this trial, within 6
weeks, positive symptoms usually decline much more
than negative or other symptoms. While certain safety
issues are often cited as limiting factors for patient accept-
ability, neither movement disorders measures nor prolac-
tin elevation was predictive of medication satisfaction.
Table 2: Correlation of PANSS factors (change from baseline 
score) and medication satisfaction at day 14 (n = 381)
r = p <
Uncontrolled hostility/excitement -.44 .00001
Positive symptoms -.39 .00001
Negative symptoms -.30 .00001
Disorganized thoughts -.30 .00001
Anxiety/depression -.14 .015
Abbreviations: PANSS, Positive and Negative Syndrome Scale.
Mean (95% confidence interval) time (days) in trial by Medication Satisfaction after 14 days of treatment (1 very dissatisfied; 7  very satisfied) Figure 1
Mean (95% confidence interval) time (days) in trial by Medication Satisfaction after 14 days of treatment (1 very dissatisfied; 7 
very satisfied).
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Future studies of second-generation antipsychotic medi-
cations should routinely include measures of medication
satisfaction. Unlike the current study, in which the meas-
ure was only administered at 2 time points, consideration
should be given to measuring satisfaction each time effi-
cacy is measured. With the advent of yet improved formu-
lations and long-acting medications designed to improve
compliance, medication satisfaction will be an outcome
of major importance.
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